Introduction {#Sec1}
============

Plants have a great potential as an expression system for therapeutic proteins: plant produced pharmaceuticals are much less likely to harbor human pathogens, production costs are relatively low and the production is easily scalable, while products can efficiently be harvested and stored (Fischer and Emans [@CR8]; Fischer et al. [@CR9]; Giddings [@CR11]). Harvesting of pharmaceuticals from plants may be greatly facilitated by directing expression of therapeutic proteins to the specialized storage organs of plants (Peeters et al. [@CR23]; Staub et al. [@CR27]; Stoger et al. [@CR28]; Van Droogenbroeck et al. [@CR33]). Many of the potential therapeutic proteins, including antibodies, require specific post-translational modifications for correct biological functioning.

Core N-glycan biosynthesis is similar in mammals and plants, but mammals and plants make different complex-type N-glycans. These differences between mammalian and plant N-linked glycan biosynthesis limit the application of therapeutic glycoproteins produced by plants since the plant produced proteins may not have the desired biological properties (Rayon et al. [@CR90]). For instance, the plant specific xylose and fucose of plant complex glycan structures may trigger an immunogenic response in mammals, making these plant specific modifications potentially immunogenic to mammals (Bencurova et al. [@CR4]). Several approaches are being pursued to optimize glycosylation in plants for pharmaceutical protein production. Plant N-glycans can be extended by mammalian type sugars through the introduction of mammalian glycosyltransferases. Via such plants, antibodies with N-glycans extended with β1,4-galactose and even sialic acid were produced (Misaki et al. [@CR21]; Fujiyama et al. [@CR10]; Bakker et al. [@CR1]; Palacpac et al. [@CR22]; Strasser et al. [@CR31]; Castilho et al. [@CR5]). The synthesis of the potentially immunogenic fucose and xylose epitopes may also be avoided by inhibiting the expression of the responsible glycosyltransferases such as demonstrated in tobacco, duckweed and moss (Huether et al. [@CR14]; Cox et al. [@CR6]; Strasser et al. [@CR30]).

Alternatively, processing of N-glycans on therapeutic proteins may be controlled by retention of the protein in the ER (Van Droogenbroeck et al. [@CR33]; Ko et al. [@CR16]). In this case processing will not proceed beyond Man~7~GlcNAc~2~ type glycans, since the enzymes involved in further N-glycan modification are located in the downstream Golgi compartments. However, also the presence of such high-mannose type glycans on plant produced and ER-retained therapeutic proteins may be undesirable for specific molecules, for example because they may contribute to a higher clearance rate of antibodies in mammalian hosts (Wright and Morrison [@CR36]; Bardor et al. [@CR3]; Ko et al. [@CR16]). Recently we identified *ALG3* gene from *Arabidopsis thaliana* as the Dol-P-Man:Man~5~GlcNAc~2~-PP-Dol α1,3-mannosyl transferase which is involved in the build-up of dolichol-linked high-mannose type glycans in the ER (Henquet et al. [@CR13]). A homozygous T-DNA insertion mutant, *alg3*-*2,* with only very low levels of wild-type *ALG3* activity was identified. In this mutant, mostly truncated aberrant Man~5~GlcNAc~2~ instead of Man~9~GlcNAc~2~ glycans are transferred from dolichol to the glycoproteins. Consequently, most processing steps in the ER are skipped and ER resident glycoproteins in *alg3*-*2* plants are almost uniformly modified by an abnormal Man~5~GlcNAc~2~ glycan (Henquet et al. [@CR13]). Both the lack of high mannose glycans and the uniformity of protein glycan structures on ER-resident proteins in *alg3*-*2* make this mutant an interesting host to test for improved quality of recombinant protein production in plants.

Previously, *Arabidopsis* plants have been described producing in seeds high levels of recombinant MBP10, a scFv-Fc directed against the Maltose Binding Protein, with a KDEL ER retention tag. N-glycans present on these antibodies were predominantly of the Man~8~GlcNAc~2~ and Man~7~GlcNAc~2~ isoforms, while in addition significant amounts of the antibody chains were not glycosylated (Van Droogenbroeck et al. [@CR33]). The MBP10 transgene was introduced through crossing into the *alg3*-*2* mutant background and the properties of MBP10, as produced in wild-type and *alg3*-*2* plants were compared.

Results {#Sec2}
=======

N-glycan profile in wild-type and *alg3*-*2* mutant *Arabidopsis* seeds {#Sec3}
-----------------------------------------------------------------------

The *alg3*-*2* plant was shown to have only very low expression of the *ALG3* gene, which results in an altered N-glycan profile on glycoproteins from leaves (Henquet et al. [@CR13]). To determine whether this phenotype is also displayed in seeds of the *alg3*-*2* mutant, the N-glycan profile of the total glycoprotein pool of wild-type and mutant *Arabidopsis* seeds was compared. Proteins were extracted from wild-type and *alg3*-*2* seeds and N-glycans were released by PNGase A treatment. Each N-glycan pool was analyzed by MALDI-TOF.

No Man~9-6~GlcNAc~2~ type glycans were detected in seeds of the mutant plants and instead particularly Man~3~GlcNAc~2~, Man~4~GlcNAc~2~ and some Man~5~GlcNAc~2~ N-glycans accumulated. This analysis does not distinguish between the wild-type Man~5~GlcNAc~2~ and the aberrant Man~5~GlcNAc~2~ from the mutant glycosylation pathway (Supplemental Fig. 1), which contains α-1,2 linked mannose residues (Henquet et al. [@CR13]). The Man~5~GlcNAc~2~ glycans from the *alg3*-*2* mutant with α-1,2 linked mannoses are sensitive to α(1,2)-mannosidase (+ManI) treatment. Therefore, the N-glycan pools were treated with α(1,2)-mannosidase (Supplemental Table 1: +ManI). Results showed that in the ManI treated N-glycan fraction from wild-type all high mannose type N-glycans had been trimmed, resulting in an increase of the ManI-resistant Man~5~GlcNAc~2~ glycan pool (Supplemental Table 1), demonstrating the effectiveness of the ManI treatment. In the *alg3-2* N-glycan fraction, the mannose type glycans were all trimmed to Man~3~GlcNAc~2~, proving that the Man~4~GlcNAc~2~ and Man~5~GlcNAc~2~ contain α-1,2 mannose residues and therefore are derived from the mutant pathway (Henquet et al. [@CR13]).Table 1Relative amounts of N-glycans on MBP10 in wild-type and *alg3*-*2* seedsGlycan structuresWild typealg3-2% of total% of totalHex3GlcNAc2n.d.n.d.Hex4GlcNAc2n.d.n.d.Hex5GlcNAc2n.d.86.1Hex6GlcNAc2n.d.n.d.Hex7GlcNAc226.613.9Hex8GlcNAc273.4n.d.Hex9GlcNAc2n.d.n.d.*n.d.* not detectable

The MALDI-TOF analysis suggests a lower level of complex type N-glycans in *alg3*-*2* seeds compare to wild type (43.4 and 55.9%, respectively), while on glycoproteins isolated from leaf tissue, the fraction of complex type N-glycans is higher compared to wild type (62.2 vs. 48.1% respectively: see Henquet et al. [@CR13]) To further investigate the level of complex glycosylation in *alg3*-*2* seeds, proteins from wild-type, *alg3*-*2* and from homozygous *cgl* mutant, which lack complex type glycans because of a defect in N-acetylglucosaminyltransferase I (von Schaewen et al. [@CR35]), were isolated from seeds and probed in an ELISA assay. The presence of glycoproteins with complex type glycans containing xylose and/or fucose can be detected with rabbit anti-horseradish peroxidase (HRP) antibodies, which are mostly directed against the complex type glycans. A difference of signal of proteins with N-linked complex type glycans was observed in the homozygous *alg3*-*2* mutant strain and wild-type plants (supplemental Fig. 2), indicating that in contrast to leaves, in seeds the mutation does affect the level of complex glycans on glycoproteins (Henquet et al. [@CR13]).

Characterization of N-glycans on MBP10 in wild-type and *alg3*-*2* seeds {#Sec4}
------------------------------------------------------------------------

MBP10 consists of a single chain Fc fused to an Fv directed against Maltose Binding Protein (MBP) and an additional KDEL sequence to retain the protein product in the ER. To determine the effect of the *alg3*-*2* mutation on recombinant antibodies retained in the ER of seeds, we crossed wild-type *Arabidopsis* transgenic plants, homozygous for the MBP10 antibody expression construct (Van Droogenbroeck et al. [@CR33]), with homozygous *alg3*-*2* mutant plants. F1 progeny plants were allowed to self pollinate and F2 plants, homozygous for both the MBP10 expression construct and the *alg3*-*2* mutation were selected as described in materials and methods. To compare the production of MBP10 in wild-type and *alg3*-*2* seeds, proteins were isolated from the seeds, separated by SDS--PAGE under reducing conditions and visualized by Commassie blue staining. Both in wild-type and *alg3*-*2* plants, similar high levels of scFv-Fc monomers migrated as major doublet bands at the expected molecular mass of \~55 kDa (Fig. [1](#Fig1){ref-type="fig"}, lanes 1 and 2), indicating that the *alg3*-*2* mutation does not significantly affect the antibody accumulation level.Fig. 1Production of MBP10 in wild-type and *alg3*-*2* seeds. Total seed protein fractions from wild-type expressing MBP10 *(lane 1)*, *alg3*-*2* expressing MBP10 *(lane 2)* and untransformed wild-type *(lane 3)* were separated by SDS--PAGE and visualized by Commassie staining

The two bands at about 55 kDa reflect the glycosylated and unglycosylated form of the scFv-Fc monomers (Van Droogenbroeck et al. [@CR33]). Indeed, in both samples, the scFv-Fc doublet collapsed to a single band after treatment with PNGase F, with the same apparent molecular size as the lower band of the original doublet (Fig. [2](#Fig2){ref-type="fig"}, lanes 3 and 6). As complex type N-glycans with Golgi specific modifications containing α1,3-linked fucose residues are resistant to PNGase F, the sensitivity of the upper band to PNGase F also indicates that the MPB10 is not decorated with complex type N-glycans, in line with it being retained to the ER. Additional confirmation that the MBP10 in wild-type contains high mannose type N-glycans came from its sensitivity to EndoH treatment (Fig. [2](#Fig2){ref-type="fig"}, compare lane 1 and 2). In contrast, N-glycans on MBP10 from *alg3*-*2* were resistant to Endo H, indicating that in *alg3*-*2* seeds, the glycans on the antibodies are not of the same high mannose type. Because the N-glycans on MPB10 in *alg3*-*2* seeds are sensitive to PNGase F but resistant to Endo H they are most likely derived from the mutant pathway in *alg3*-*2* (Fig. [2](#Fig2){ref-type="fig"}, compare lane 5 and 6) in which an aberrant Man~5~GlcNAc~2~ glycan is transferred from lipid to protein.Fig. 2*N*-glycan analysis of MBP10 in wild-type and *alg3*-*2* seeds. Isolated total seed protein fractions from wild-type expressing MBP10 *(lane 1)*, *alg3*-*2* expressing MBP10 *(lane 4)*, before and after overnight incubation with EndoH *(lanes 2* and *5)* or PNGase F *(lanes 3* and *6)*, were separated by SDS--PAGE, and visualized by Commassie staining

In complementary experiments, the N-glycans on MBP produced in wild-type or *alg3*-*2* seeds were analyzed by MALDI-TOF. The MBP10 protein from both wild-type and *alg3*-*2* was isolated from a reducing denaturing SDS--PAGE gel, treated with trypsin and the peptide mixture was subjected to analysis by MALDI-TOF. In contrast to earlier LCMS analysis of N-glycans on MBP10 in wild-type (Van Droogenbroeck et al. [@CR33]), no partial tryptic glycopeptides masses were detected in our analysis. Similar as to previously observed (Van Droogenbroeck et al. [@CR33]), the most abundant glycans on scFv-Fc isolated from wild-type seeds were Man~8~GlcNAc~2~ and Man~7~GlcNAc~2~ (Table [1](#Tab1){ref-type="table"}). The scFv-Fc glycopeptides from *alg3*-*2* seeds were mostly modified by Man~5~GlcNAc~2~. However, also a significant pool was decorated with Hex~7~GlcNAc~2~ type glycans which could be wild type Man~7~GlcNAc~2~ or Glc~2~Man~5~GlcNAc~2~ glycans. This needs further investigation.

Underglycosylation of MBP from wild type and *alg3*-*2* seeds {#Sec5}
-------------------------------------------------------------

To determine the amount of nonglycosylated MBP10 derived from wild type and *alg3*-*2* seeds, the MBP10 protein was isolated with a Protein A column, deglycosylated with PNGase and treated with trypsin. The MBP10 peptide mixtures from wild type and *alg3*-*2* were subjected LC--MS analysis. Since asparagine (N) is converted to aspartic acid (D) in this PNGase F reaction, glycosylation sites can be identified by a mass increase of 1 Dalton. This mass difference can be measured by Q-TOF LC--MS and the ratio of N and D gives an indication for the ratio between non-glycosylated and deglycosylation of MBP10. From Fig. [2](#Fig2){ref-type="fig"} it was already visible that both MBP10 variants contain nonglycosylated as well as glycosylated antibodies. The results show a significant increase in the amount of nonglycosylated MBP10 isolated from *alg3*-*2* seeds (31.0% ± 2.3%) as compared to wild type seeds (22.4% ± 0.7%) (Fig. [3](#Fig3){ref-type="fig"}, Supplemental Fig. 3).Fig. 3Level of underglycosylated MBP10 isolated from wild-type and *alg3*-*2* seeds determined by Q-TOF LCMS. MBP10 isolated from total seed protein fractions from wild-type and *alg3*-*2* expressing MBP10 after overnight incubation with PNGase F were analyzed by Q-TOF LC--MS. The ratio of N-D resulting from the PNGase reaction gives the ratio between non- and deglycosylation of MBP10

MBP10 expression in seeds affects glycosylation of endogenous glycoproteins {#Sec6}
---------------------------------------------------------------------------

The fraction of underglycosylated MBP10 in both wild type and *alg3*-*2* may suggest that the glycosylation capacity of the cells in developing seeds may not be able to cope with the elevated level of glycoprotein expression. To determine whether this effect of high heterologous MBP10 production levels on glycosylation also affects endogenous ER resident proteins, the glycosylation of protein disulfide isomerase (PDI) was investigated in wild-type and *alg3*-*2* seeds from plants with or without seed specific MBP10 expression. Indeed, PDI showed no signs of underglycosylation in wild type, while underglycosylation was weak in wild-type + MBP10, stronger in *alg3*-*2* and strongest in *alg3*-*2* + MBP10 (Fig. [4](#Fig4){ref-type="fig"}). Apparently, the ectopic MBP10 expression in both wild type and *alg3*-*2* causes competition for glycosylation activity, resulting in PDI underglycosylation in the ER. Glycan analysis showed that the glycans of PDI from wild type were cleaved by EndoH (data not shown), while the glycans on MBP10 from *alg3*-*2* seeds were resistant to EndoH treatment, indicating that these are not normal high-mannose type glycans and therefore most likely derived from the mutant pathway (aberrant Man~5-3~GlcNAc~2~ type). A similar difference was observed for glycans on PDI in WT and *alg3*-*2* leaf protein extracts (Henquet et al. [@CR13]).Fig. 4PDI in wild-type and *alg3*-*2* seeds with or without MBP10 expression Western blot analysis of PDI in wild-type and *alg3*-*2* seeds with or without MBP10 expression. Proteins were isolated from wild-type and *alg3*-*2* seeds and subjected to immunoblotting with anti-PDI. \* indicates under glycosylated PDI protein

Glycan occupancy of MBP10 dimers from wild type and *alg3*-*2* {#Sec7}
--------------------------------------------------------------

Since the results show that MBP10 scFv-Fc monomers from both wild type and *alg3*-*2* mutant seeds exist in glycosylated and unglycosylated states, it was of interest to determine the fraction MBP10 dimers consisting of homo-glycosylated, hetero-glycosylated and homo-unglycosylated MPB10 scFv-Fc dimers in wild type and *alg3*-*2* seeds. We therefore performed native mass spectrometric analysis on intact scFv-Fc dimers (Heck [@CR12]). The mass difference between the different glycoforms in each of the samples corresponded with the mass of the major N-glycan present on wild type or *alg3*-*2* MBP10 (Hex~8~GlcNAc~2~ and Hex~5~GlcNAc~2,~ respectively). The results show that MBP10 dimers from both wild type and *alg3*-*2* contain either no, one or two glycans (Table [2](#Tab2){ref-type="table"}; H0, H1, H2). This ratio is close to the theoretical ratio between H0:H1:H2 based on dimerisation of unglycosylated and glycosylated chains in a random manner, which suggests no preference in dimer formation (Supplemental Table 2).Table 2Glycan occupancy on MBP10 dimers (zero glycans: H0, one glycan: H1, two glycans H2) in wild-type and *alg3*-*2* seedsSampleMolecular mass (Da)Mass differenceExpected mass difference (Da)Wild type H0107713.2----Wild type H1109383.5+1670.31702.0Wild type H2111080.2+1696.71702.0*alg3*-*2* H0107666.9--*alg3*-*2* H1108882.6+1215.71216.0*alg3*-*2* H2110092.0+1209.41216.0Glycan occupancy was based on the major mass difference between the unglycosylated form (H0) and other identified total MPB10 dimer masses. The theoretical molecular weight of unglycosylated MPB10 scFv-Fc dimer (H0): 107584.4 Da. Expected mass difference is based on the most common occurring glycan on MBP10 in wild-type (Hex8GlcNAc2) or *alg3*-*2* (Hex5GlcNAc) (see [Table 1](#Tab1){ref-type="table"}

Binding of MBP10 from wild-type and *alg3*-*2* to the antigen {#Sec8}
-------------------------------------------------------------

The Fv of MBP10 contains a binding site to the maltose binding protein (Van Droogenbroeck et al. [@CR33]). We tested whether the affinity of MBP10 to maltose binding protein was affected by the difference in glycan structure on MBP10 in wild type and MBP10 in the *alg3*-*2* mutant plants. Purified MBP10 antibodies from both wild type and *alg3*-*2* were tested for reactivity with maltose binding protein by ELISA for binding against MBP antigen. The results show that MBP10 from *alg3*-*2* has a slightly lower binding affinity for the antigen than MBP10 from wild type seeds at high concentrations but that they are indistinguishable at lower concentrations (Supplemental Fig. 4).

Discussion {#Sec9}
==========

MBP10 expression affects N-glycosylation levels in seeds {#Sec10}
--------------------------------------------------------

Here we have compared the production of the MBP10 antibody in wild type and *alg3*-*2* mutant background. The *alg3*-*2* background has as potential advantage that glycan modifications on ER resident proteins are highly uniform. On MBP10 protein, next to the high level of aberrant Man5GlcNac2 glycan, a low level of normal high mannose type N-glycans was detected, which apparently resulted from leakage of the *alg3*-*2* mutation. (Henquet et al. [@CR13]).

The total amount of complex type N-glycans, as detected by MALDI-TOF, was lower in *alg3*-*2* seeds compared to wild-type (Supplemental Table 1: 43.4% in *alg3*-*2* compared to 55.9% in wild-type). In contrast, in leaves the relative level of complex glycosylation was similar for wild-type and the *alg3*-*2* mutant (Henquet et al. [@CR13]). The difference in level of complex N-glycans between wild type and *alg3*-*2* seed proteins was confirmed by an ELISA assay (Supplemental Fig. 2). The difference could be related to a reduced substrate specificity of N-acetylglucosaminyltransferase I (GnTI) for the aberrant Man~3~GlcNAc~2~ N-glycans which are produced in *alg3*-*2* after trimming of aberrant N-glycan structures by ManI. Indeed, in vitro experiments have shown that, for both plant and mammalian GnTI, both substrates can be used but that Man~5~GlcNAc~2~ is the preferred substrate (Schachter et al. [@CR24]; Strasser et al. [@CR29]). It could be that with the elevated secretion activity in seeds compared to leaves, the GnTI levels in seeds are more limiting than in leaves. Alternatively, or in addition, it could be that the elevated secretion activity in seeds favors sequestering of proteins with aberrant glycans to ER derived protein storage bodies, resulting in diminished transport of endogenous proteins to and through the Golgi.

The levels of accumulate MBP10 protein were similar in *alg3*-*2* and wild type seeds (Fig. [1](#Fig1){ref-type="fig"}). However, the production of MBP10 in seeds did affect the glycosylation status of endogenous glycoproteins like PDI (Fig. [4](#Fig4){ref-type="fig"}). This effect seems to be stronger in *alg3*-*2* seeds with MBP10 expression than in wild type seeds with MBP10 expression. The results suggest a limit to the N-glycosylation capacity in relation to the elevated protein secretion activity in the ER of developing seeds. In the *alg3*-*2* background, the under glycosylated levels of MBP10 and PDI were even higher, which may be caused by reduced affinity of the oligosaccharyltransferase (OST) complex for lipid bound aberrant type glycans.

Aberrant glycans have no effect on physical properties of MBP10 {#Sec11}
---------------------------------------------------------------

The overall binding properties of MBP10 as produced in the *alg3*-*2* background were not much different from those of MBP10 as produced in wild type seeds (Supplemental Fig. 4). Although the binding of MBP10 to the maltose binding protein is not dependent on dimerisation of the antibody, it was of interest to determine whether dimer formation showed preferences for homodimer (fully glycosylated or fully unglycosylated) or heterodimer (one glycosylated and one not glycosylated) formation. Results showed both homodimer and heterodimer antibodies are present. The relative abundance, based on peak intensities of each of the glycoforms, was similar to the predicted abundance based on random associations (Table [2](#Tab2){ref-type="table"} and Supplemental Table 2), indicating that the difference in glycan structure is of no influence in dimerisation.

Materials and methods {#Sec12}
=====================

Plant materials and growth conditions {#Sec13}
-------------------------------------

Seeds of *Arabidopsis* thaliana lines were sown on 9 cm 0.8% daishin agar Petri dishes and placed in a cold room at 4°C for 2 days in the dark to promote uniform germination. Germination and plant culture were performed in a climate chamber (20/15°C day/night temperatures; 250 μmol light m^−2^s^−1^ at plant level during 12 h/day and 75% relative humidity).

Construction of *alg3*-*2*/MBP plants {#Sec14}
-------------------------------------

The *alg3*-*2*/MBP plants were obtained by crossing *alg3*-*2* mutant plants with wild-type Col0 plants containing the MBP antibody gene. F2 generation was screened for homozygous *alg3*-*2* T-DNA insertion with PCR on genomic DNA using the forward primer Alg3-F2.2 (5′-CGTTCAGTGATGTATCAGCCTCACGG-3′) and the reverse primer Alg3-R2 (5′-GGATTTAGGGTGTTCTTTGAGCTGATAAGG-3′). Proteins from seeds from homozygous *alg3*-*2* F2 plants were separated on SDS--PAGE gel and stained with Commassie Brilliant blue to select for plants containing the anti-MBP antibody.

SDS--PAGE and immunoblotting {#Sec15}
----------------------------

Plant material was ground in liquid nitrogen, resuspended in 10 μl phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 10 mM Na~2~HPO~4~, 2 mM KH~2~PO~4~, pH 7.4) per mg of plant material and centrifuged. An aliquot of the supernatant was immediately mixed with SDS--polyacrylamide gel electrophoresis (PAGE) loading buffer, denatured at 95°C for 5 min and subjected to SDS--PAGE (8 or 12.5%) under reducing conditions. Protein gel blotting was performed using polyvinylidene difluoride membranes, blocked with 5% (w/v) nonfat dry milk in Tris-buffered saline (20 mM Tris--HCl, pH 7.6, and 137 mM NaCl) with 0.05% Tween 20. The membranes were probed with anti-PDI (1:5000; Rosebiotech). Detection of bound primary antibodies was performed with BCIP/NBT after incubation with goat anti-rabbit antibodies. PNGase F and Endo H were purchased from New England Biolabs for glycosylation analysis of PDI and MBP10 and used according to the suggested methods along with the manufacturer's recommended buffers. The reactions were terminated by boiling in SDS-loading buffer.

Purification of the MBP10 antibody {#Sec16}
----------------------------------

MBP10 antibodies were purified from crude seed extracts with a Vivapure Miniprep A kit (Sartorius) according to the manufacturer's protocol.

ELISA {#Sec17}
-----

Microtiter plates were coated with protein extract from seeds overnight at 4°C in 0.1 M sodium carbonate buffer, pH 9.6. The plates were washed with phosphate-buffered saline (PBS) containing 0.05% Tween 20 and blocked with PBS-T containing 5% skimmed milk for 1 h at RT. After the washing the plates were incubated for 1 h at RT with polyclonal anti-HRP antibody (Sigma) diluted 1:2,000. Detection of bound primary antibodies was performed with AP substrate after incubation with goat anti-rabbit antibodies.

Isolation of N-glycans and α(1,2)-mannosidase treatment {#Sec18}
-------------------------------------------------------

Seeds of *Arabidopsis* plants were used for N-glycans analysis. Proteins for N-glycan purification were extracted from 100 mg of seeds and digested with pepsin. Bound N-glycans were released by PNGase A (Roche) as described previously (Bakker et al. [@CR2]). Aspergillus satoi α(1,2)-mannosidase (10 mU/ml; Pro-enzyme, Glyko) digestions were performed in the supplied buffer for 24 h at 37°C. Reactions were then diluted with 0.5 ml of milliQ water and desalted by passage through a 500 mg C18 column (Varian).

N-glycan analysis {#Sec19}
-----------------

Purified N-glycans were dissolved in 5 mM NaAc and mixed with an equal volume of 1% 2,5-dihydroxybenzoic acid in 50% acetonitrile. One-microliter aliquots were spotted onto a stainless-steel sample plate and dried under a stream of air at room temperature. Positive-ion MALDI-TOF spectra of \[M + Na\] + adducts were recorded on an Ultraflex mass spectrometer (Bruker, Billerica, MA) fitted with delayed extraction and a nitrogen laser (337 nm). A maltodextrin series was used as an external molecular weight standard. Spectra were generated from the sum of at least 1,000 laser pulses.

MALDI glycopeptide analysis {#Sec20}
---------------------------

The protein A purified MBP10 protein from both wild type and *alg3*-*2* was isolated from a reducing denaturing SDS--PAGE gel, treated with trypsin and the peptide mixture was desalted using C18 zip-tip (Millipore). The purified (glyco)peptide mixture was dissolved in milliQ water and spotted onto a stainless-steel MALDI target plate. Samples spotted onto MALDI plate were overlaid with an equal volume of dihydroxybenzoic acid (DHB, 2 mg/ml 30% ACN with 0.1% TFA) and allowed to dry in air at room temperature. Positive-ion MALDI-TOF spectra were recorded on an Ultraflex mass spectrometer (Bruker, Billerica, MA) fitted with delayed extraction and a nitrogen laser (337 nm). A maltodextrin series was used as an external molecular weight standard. Spectra were generated from the sum of at least 1,000 laser pulses. The glycans on the glycopeptides were subsequently deduced by subtracting the mass of the predicted tryptic scFv-Fc peptide (EEQYNSTYR; 1188.5 Da) from the observed masses of the glycopeptides.

Native mass spectrometry {#Sec21}
------------------------

The buffers of the proteins were exchanged to 100 mM ammonium acetate pH 7.5, using ultrafiltration units with a cutoff of 10,000 Da (Millipore, Bedford, USA). All antibodies were analyzed at a concentration of 5 μM. Electrospray ionization capillaries were prepared in house as described previously (van den Heuvel et al. [@CR32]). Analysis was performed on an LCT in positive ion mode (Waters, UK). Typically mass spectra were recorded with a capillary voltage of 1.2 kV and a cone voltage of 200 V. The pressure in the source region was raised to approximately 7 mbar, the pressure in the ToF was 2.7 × 10^−6^ mbar. All spectra were calibrated using a solution of 25 mg/ml cesium iodide in MilliQ water.

Electronic supplementary material {#AppESM1}
---------------------------------

Below is the link to the electronic supplementary material.
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